Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers (2018)

Peer-Reviewed Study · Muñoz J, Ballester MR, Antonijoan RM, Gich I, Rodríguez M, Coll RA, Gold S, et al. · January 2018

Muñoz J et al., 2018-01: Phase I trial in 54 healthy volunteers comparing fixed 18 mg and 36 mg ivermectin tablets with the standard weight-based 150-200 mcg/kg dose. It characterises exposure for doses well above the approved mg/kg dose and is one of the human PK datasets behind fixed-dose proposals.

We conducted a phase I clinical trial with 54 healthy adult volunteers who sequentially received 2 experimental treatments using a new 18 mg ivermectin tablet in a fixed-dose strategy of 18 and 36 mg single dose regimens, compared to the standard, weight based 150-200 μg/kg, regimen.

Muñoz J et al., 2018-01: Phase I trial in 54 healthy volunteers comparing fixed 18 mg and 36 mg ivermectin tablets with the standard weight-based 150-200 mcg/kg dose. It characterises exposure for doses well above the approved mg/kg dose and is one of the human PK datasets behind fixed-dose proposals. C1 PK. Study type: phase I, open-label, sequential-dose clinical trial; N=54 healthy adults; Spain (Hospital Universitari de la Santa Creu i Sant Pau / Barcelona Institute for Global Health). Doses: single 18 mg and single 36 mg fixed-dose tablet vs standard weight-based 150-200 mcg/kg; oral; single dose. Funder/manufacturer: Liconsa (Chemo Group) supplied the study drug and Exeltis France funded it, per the paper's competing-interests statement: 'EC and SG are members of Chemo Group, which includes Liconsa, the manufacturer of the study drug and Exeltis France, the funding source'. Comparator: standard weight-based 150-200 mcg/kg ivermectin. Quote from the abstract (PubMed record). Study type: controlled study.